Valeant Pharmaceuticals, whose business model has been criticized by buyout target Allergan, posted third-quarter earnings that exceeded expectations.
from WSJ.com: US Business http://ift.tt/1wjwMdZ
via IFTTT
from WSJ.com: US Business http://ift.tt/1wjwMdZ
via IFTTT
No comments:
Post a Comment